Harry M. Olson

2.7k total citations · 1 hit paper
16 papers, 2.0k citations indexed

About

Harry M. Olson is a scholar working on Cardiology and Cardiovascular Medicine, Genetics and Small Animals. According to data from OpenAlex, Harry M. Olson has authored 16 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Cardiology and Cardiovascular Medicine, 4 papers in Genetics and 2 papers in Small Animals. Recurrent topics in Harry M. Olson's work include Chemotherapy-induced cardiotoxicity and mitigation (4 papers), Virus-based gene therapy research (3 papers) and Computational Drug Discovery Methods (2 papers). Harry M. Olson is often cited by papers focused on Chemotherapy-induced cardiotoxicity and mitigation (4 papers), Virus-based gene therapy research (3 papers) and Computational Drug Discovery Methods (2 papers). Harry M. Olson collaborates with scholars based in United States, United Kingdom and Belgium. Harry M. Olson's co-authors include Denise E. Robinson, Graham R. Betton, Patrick D. Lilly, A. M. Monro, Gerald J. Kolaja, Karluss Thomas, William M. Bracken, Allen H. Heller, Peter J. Smith and Bruce M. Berger and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Toxicology and Applied Pharmacology and Experimental Biology and Medicine.

In The Last Decade

Harry M. Olson

15 papers receiving 1.8k citations

Hit Papers

Concordance of the Toxicity of Pharmaceuticals in Humans ... 2000 2026 2008 2017 2000 400 800 1.2k

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harry M. Olson United States 9 480 452 346 302 270 16 2.0k
Graham R. Betton United Kingdom 15 583 1.2× 501 1.1× 87 0.3× 201 0.7× 286 1.1× 34 2.2k
Gerald J. Kolaja United States 10 397 0.8× 474 1.0× 44 0.1× 152 0.5× 241 0.9× 16 1.6k
Bruce M. Berger United States 5 369 0.8× 449 1.0× 43 0.1× 185 0.6× 242 0.9× 9 1.6k
Peter Greaves United Kingdom 30 938 2.0× 235 0.5× 83 0.2× 386 1.3× 78 0.3× 78 2.7k
Caroline Aninat France 19 855 1.8× 620 1.4× 28 0.1× 329 1.1× 108 0.4× 34 2.2k
Christophe Chesné France 31 802 1.7× 718 1.6× 20 0.1× 513 1.7× 140 0.5× 80 3.0k
Philip Hewitt Germany 27 773 1.6× 452 1.0× 16 0.0× 246 0.8× 202 0.7× 74 2.2k
Terry R. Van Vleet United States 20 609 1.3× 181 0.4× 24 0.1× 226 0.7× 201 0.7× 35 1.5k
Roque Bort Spain 24 1.6k 3.3× 732 1.6× 39 0.1× 484 1.6× 79 0.3× 39 3.1k
Robyn L. Fisher United States 24 347 0.7× 504 1.1× 33 0.1× 202 0.7× 26 0.1× 47 1.4k

Countries citing papers authored by Harry M. Olson

Since Specialization
Citations

This map shows the geographic impact of Harry M. Olson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry M. Olson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry M. Olson more than expected).

Fields of papers citing papers by Harry M. Olson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry M. Olson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry M. Olson. The network helps show where Harry M. Olson may publish in the future.

Co-authorship network of co-authors of Harry M. Olson

This figure shows the co-authorship network connecting the top 25 collaborators of Harry M. Olson. A scholar is included among the top collaborators of Harry M. Olson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry M. Olson. Harry M. Olson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Olson, Harry M., et al.. (2001). Hormesis - A Pharmaceutical Industry Perspective. Critical Reviews in Toxicology. 31(4-5). 659–661. 5 indexed citations
2.
Olson, Harry M., Graham R. Betton, Denise E. Robinson, et al.. (2000). Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals. Regulatory Toxicology and Pharmacology. 32(1). 56–67. 1417 indexed citations breakdown →
3.
Jacobson‐Kram, David, Harry M. Olson, Leslie Recio, et al.. (2000). Review Article: Use of Transgenic Animals for Carcinogenicity Testing: Considerations and Implications for Risk Assessment. Toxicologic Pathology. 28(3). 482–499. 53 indexed citations
4.
Olson, Harry M., et al.. (1998). The predictivity of the toxicity of pharmaceuticals in humans from animal data — an interim assessment. Toxicology Letters. 102-103. 535–538. 56 indexed citations
5.
Dean, Jack H. & Harry M. Olson. (1993). The integration of investigative toxicology in the drug discovery process. Biology of the Cell. 77(1). 3–8. 2 indexed citations
6.
Hunt, Steven C., et al.. (1991). Effects of long term 2% fish oil supplements on tissue fatty acids, phospholipids, cholesterol, and arterial histology in Japanese quail (Coturnix coturnix japonica).. PubMed. 18(6). 291–314. 7 indexed citations
7.
Olson, Harry M., et al.. (1980). Alterations of lactate dehydrogenase isoenzymes with subacute adriamycin toxicity.. PubMed. 63(11-12). 2057–9. 8 indexed citations
8.
Olson, Harry M. & Charles C. Capen. (1978). Chemoresponsiveness of Moloney sarcoma virus-induced osteosarcoma to adriamycin in the rat.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 38(6). 1561–7. 4 indexed citations
9.
Olson, Harry M.. (1978). Chronic cardiotoxicity of doxorubicin (Adriamycin) in the rat: Morphologic and biochemical investigations. Toxicology and Applied Pharmacology. 44(3). 605–616. 59 indexed citations
10.
Olson, Harry M. & Charles C. Capen. (1977). Intratibial Moloney Sarcoma Virus-Induced Osteosarcoma in the Rat: Tumor Incidence and Pathologic Evaluation2. JNCI Journal of the National Cancer Institute. 58(2). 433–437. 4 indexed citations
11.
Olson, Harry M. & C. C. Capen. (1977). Virus-induced animal model of osteosarcoma in the rat: Morphologic and biochemical studies.. PubMed. 86(2). 437–58. 16 indexed citations
12.
Rosenoff, Stephen H., et al.. (1975). Brief Communication : Adriamycin-Induced Cardiac Damage in the Mouse: A Small-Animal Model of Cardiotoxicity. JNCI Journal of the National Cancer Institute. 55(1). 191–194. 92 indexed citations
13.
Young, David M., Jessica Fioravanti, Harry M. Olson, & David J. Prieur. (1975). Chemical and morphologic alterations of rabbit bone induced by adriamycin. Calcified Tissue International. 18(1). 47–63. 24 indexed citations
14.
Olson, Harry M., David M. Young, David J. Prieur, A Leroy, & Reginald L. Reagan. (1974). Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits.. PubMed. 77(3). 439–54. 189 indexed citations
15.
Prieur, David J., Harry M. Olson, & David M. Young. (1974). Lysozyme deficiency-an inherited disorder of rabbits.. PubMed. 77(2). 283–98. 27 indexed citations
16.
Prieur, David J., David M. Young, Reginald L. Reagan, & Harry M. Olson. (1973). Induction of Anomalous Lysosomes in the Renal Papillae of Beige Mice by Experimental Potassium Deficiency. Experimental Biology and Medicine. 144(2). 683–687. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026